Study of GS-0415 and How It Works in People With HIV
← catalyst calendarNCT07719491 · readout ≤ 1,108 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
112estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | Aug 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- HIV -1 Infection
Interventions
- Drug: GS-0415
- Drug: GS-0415 Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)
measured First dose date up to 99 days
Percentage of Participants Experiencing Clinical Laboratory Abnormalities
measured First dose date up to 99 days
Serum Pharmacokinetic (PK) Parameter (After Single Ascending Dose (SAD)): AUCinf of GS-0145
measured Up to 43 days
Serum PK Parameters (SAD): Cmax of GS-0145
measured Up to 43 days
Serum PK Parameters Multiple Ascending Dose (MAD): Dose 1 and Dose 5: AUCtau of GS-0145
measured Up to 99 days
Serum PK Parameters MAD: Dose 1 and Dose 5: Cmax of GS-0145
measured Up to 99 days
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed